Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Nasopharyngeal Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1Breast Neoplasms 1Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer 1Advanced Malignant Tumors 1

Interventions

Cisplatin 51Gemcitabine 24Radiotherapy, Intensity-Modulated 21Docetaxel 20Fluorouracil 15camrelizumab 12Drug Therapy 11Radiotherapy 10toripalimab 8Chemoradiotherapy 8Capecitabine 8apatinib 7Induction Chemotherapy 7nimotuzumab 6endostar protein 6Endostatins 6sintilimab 5nedaplatin 5Bevacizumab 5fludarabine 4Cyclophosphamide 4spartalizumab 3fludarabine phosphate 3cisplatin-guanosine adduct 3SSRP1 protein, human 3Paclitaxel 3Injections 3Endoscopy 3tislelizumab 2Vitamin B 12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Nasopharyngeal Carcinoma × SHR-1701 × Clear all
NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
91 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05020925 2021-08-25

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡